FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896791420> ?p ?o ?g. }

• W2896791420 endingPage "e11502" @default.
• W2896791420 startingPage "e11502" @default.
• W2896791420 abstract "Background Despite intensive efforts to engage people living with HIV in the United States, less than half of the youth aged 13 to 24 years achieve viral suppression. There is a clear and continued need for innovative behavioral programs that support optimizing adherence among young persons with HIV. Objective There are 3 phases of this project. Phase 1 involves conducting focus groups to obtain feedback from youth about an existing technology-based antiretroviral therapy (ART) adherence intervention. Phase 2 will be used to conduct beta testing with youth to refine and finalize the YouTHrive (YT) intervention. Phase 3 is a randomized controlled trial (RCT) to test the efficacy of the YT intervention among youth living with HIV (YLWH). Methods In phase 1, we will conduct 6 focus groups with approximately 8 youths (aged 15-19 years) and young adults (aged 20-24 years), each in 3 US cities to obtain (1) feedback from YLWH about the look and feel and content of an existing adult-focused Web-based ART adherence intervention and (2) suggestions for adapting the intervention for YLWH similar to themselves. Phase 2 will involve updating the existing intervention to include features and functionality recommended by YLWH in phase 1; it will conclude with beta testing with 12 participants to gain feedback on the overall design and ensure proper functionality and ease of navigation. For phase 3, we will enroll 300 YLWH in 6 US cities (Atlanta, Chicago, Houston, New York City, Philadelphia, and Tampa) into a 2-arm prospective RCT. Participants will be randomized 1:1 to YT intervention or control group. The randomization sequence will be stratified by city and use random permuted blocks of sizes 2 and 4. Participants randomized to the control condition will view a weekly email newsletter on topics related to HIV, with the exception of ART adherence, for 5 months. Participants randomized to the YT intervention condition will be given access to the YT site for 5 months. Study assessments will occur at enrollment and 5, 8, and 11 months post enrollment. The primary outcome that will be assessed is sustained viral load (VL), defined as the proportion of participants in each study arm who have suppressed VL at both the 5- and 11-month assessment; the secondary outcome that will be assessed is suppressed VL at both the 5- and 11-month assessment between drug-using and nondrug-using participants assigned to the YT intervention arm. Results Participant recruitment began in May 2017 for phase 1 of the study. The data collection for aim 3 is anticipated to end in April 2020. Conclusions The efficacy trial of the YT intervention will help to fill gaps in understanding the efficacy of mobile interventions to improve ART adherence among at-risk populations. Trial Registration ClinicalTrials.gov NCT03149757; https://clinicaltrials.gov/ct2/show/NCT03149757 (Archived by WebCite at http://www.webcitation.org/73pw57Cf1) International Registered Report Identifier (IRRID) DERR1-10.2196/11502" @default.
• W2896791420 created "2018-10-26" @default.
• W2896791420 creator A5002124291 @default.
• W2896791420 creator A5008686211 @default.
• W2896791420 creator A5019215882 @default.
• W2896791420 creator A5029323925 @default.
• W2896791420 creator A5031310041 @default.
• W2896791420 creator A5064753304 @default.
• W2896791420 creator A5081519572 @default.
• W2896791420 date "2019-07-30" @default.
• W2896791420 modified "2023-10-14" @default.
• W2896791420 title "Connecting Youth and Young Adults to Optimize Antiretroviral Therapy Adherence (YouTHrive): Protocol for a Randomized Controlled Trial" @default.
• W2896791420 cites W1573808323 @default.
• W2896791420 cites W1590614923 @default.
• W2896791420 cites W1899476743 @default.
• W2896791420 cites W1911576916 @default.
• W2896791420 cites W1964158155 @default.
• W2896791420 cites W1967390644 @default.
• W2896791420 cites W1971232672 @default.
• W2896791420 cites W1980327212 @default.
• W2896791420 cites W1980458358 @default.
• W2896791420 cites W1982363513 @default.
• W2896791420 cites W1987861648 @default.
• W2896791420 cites W1991106348 @default.
• W2896791420 cites W1991159879 @default.
• W2896791420 cites W1995576284 @default.
• W2896791420 cites W2005732969 @default.
• W2896791420 cites W2012796013 @default.
• W2896791420 cites W2014711375 @default.
• W2896791420 cites W2015884554 @default.
• W2896791420 cites W2018633959 @default.
• W2896791420 cites W2020213614 @default.
• W2896791420 cites W2027257317 @default.
• W2896791420 cites W2035342780 @default.
• W2896791420 cites W2043705607 @default.
• W2896791420 cites W2045245633 @default.
• W2896791420 cites W2046347837 @default.
• W2896791420 cites W2048533792 @default.
• W2896791420 cites W2057766220 @default.
• W2896791420 cites W2061871804 @default.
• W2896791420 cites W2065765677 @default.
• W2896791420 cites W2066440236 @default.
• W2896791420 cites W2075006538 @default.
• W2896791420 cites W2075519239 @default.
• W2896791420 cites W2085381642 @default.
• W2896791420 cites W2085454038 @default.
• W2896791420 cites W2108276595 @default.
• W2896791420 cites W2138871559 @default.
• W2896791420 cites W2140828104 @default.
• W2896791420 cites W2148958761 @default.
• W2896791420 cites W2152264416 @default.
• W2896791420 cites W2154112620 @default.
• W2896791420 cites W2155397747 @default.
• W2896791420 cites W2166738638 @default.
• W2896791420 cites W2319207928 @default.
• W2896791420 cites W2336898845 @default.
• W2896791420 cites W2340311148 @default.
• W2896791420 cites W2531743908 @default.
• W2896791420 cites W2564699225 @default.
• W2896791420 cites W2613321279 @default.
• W2896791420 cites W2617126691 @default.
• W2896791420 cites W2625286693 @default.
• W2896791420 cites W2660889248 @default.
• W2896791420 cites W2768404199 @default.
• W2896791420 cites W2792799562 @default.
• W2896791420 cites W2806997439 @default.
• W2896791420 cites W4245172869 @default.
• W2896791420 doi "https://doi.org/10.2196/11502" @default.
• W2896791420 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6691670" @default.
• W2896791420 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31364601" @default.
• W2896791420 hasPublicationYear "2019" @default.
• W2896791420 type Work @default.
• W2896791420 sameAs 2896791420 @default.
• W2896791420 citedByCount "9" @default.
• W2896791420 countsByYear W28967914202020 @default.
• W2896791420 countsByYear W28967914202021 @default.
• W2896791420 countsByYear W28967914202022 @default.
• W2896791420 countsByYear W28967914202023 @default.
• W2896791420 crossrefType "journal-article" @default.
• W2896791420 hasAuthorship W2896791420A5002124291 @default.
• W2896791420 hasAuthorship W2896791420A5008686211 @default.
• W2896791420 hasAuthorship W2896791420A5019215882 @default.
• W2896791420 hasAuthorship W2896791420A5029323925 @default.
• W2896791420 hasAuthorship W2896791420A5031310041 @default.
• W2896791420 hasAuthorship W2896791420A5064753304 @default.
• W2896791420 hasAuthorship W2896791420A5081519572 @default.
• W2896791420 hasBestOaLocation W28967914201 @default.
• W2896791420 hasConcept C141071460 @default.
• W2896791420 hasConcept C144133560 @default.
• W2896791420 hasConcept C15744967 @default.
• W2896791420 hasConcept C159110408 @default.
• W2896791420 hasConcept C162853370 @default.
• W2896791420 hasConcept C168563851 @default.
• W2896791420 hasConcept C1862650 @default.
• W2896791420 hasConcept C205545832 @default.
• W2896791420 hasConcept C27415008 @default.
• W2896791420 hasConcept C2780665704 @default.
• W2896791420 hasConcept C512399662 @default.

• next